In 2021, Kong et al. [22] confirmed it, showing that allergic symptoms can exacerbate behavioral symptoms, and omalizumab may be a promising symptomatic treatment for children with both ASD and IgE-mediated allergies. This evidence concerns the gene IGHE and allergic disease.